The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2)

<div>The process of antibody-dependent enhancement (ADE) in lung cells. Entry of SARS-CoV-2, which is mediated by ACE-2 receptors on lung cells, further actuates inflammatory cascades through the production of pathogen-specific antibodies followed by ADE. ADE consequently induces lung pathology through the engagement with Fc receptors expressed on several immune cells, viz., monocytes and macrophages. Internalization of ADE-induced immune cascades can foster inflammation and tissue damage by modulating the inflammatory factors in lung cells.</div>

BioMed Research International

fig3

Figure 3

Figure 3: The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) 

Figure 3 | The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) 